title: Proteinuria and Albuminuria During and After Paricalcitol Treatment in Chronic Kidney Disease Patients.
abstract: Data on paricalcitol lowering albuminuria and proteinuria already exist; however, it is unclear how paricalcitol withdrawal affects both. Forty-two nondialysis chronic kidney disease (CKD) patients (29 men) aged 62.3 ± 12 years completed the study. CKD patients with proteinuria and intact parathyroid hormone ≥65 pg/mL received paricalcitol (1 μg/day po) for 6 months. After paricalcitol withdrawal we followed them for 6 more months. Paricalcitol treatment significantly reduced urinary albumin/creatinine ratio (UACR), 24-hour albuminuria (24hA), and 24-hour proteinuria (24hP). Six months after drug withdrawal UACR increased significantly, 24hA and 24hP did not change significantly. Serum creatinine and cystatin C significantly increased during treatment, and estimated glomerular filtration rate (eGFR) decreased. After drug withdrawal serum creatinine, cystatin C, and eGFR did not change significantly. In conclusion, 6-month paricalcitol treatment (1 μg/day) in nondialysis CKD patients significantly reduced albuminuria and proteinuria. Six months after paricalcitol withdrawal 24hA and 24hP did not change significantly. Kidney function decreased during paricalcitol treatment; after paricalcitol withdrawal it remained stable. The unaltered values of 24hA, 24hP, and kidney function after paricalcitol withdrawal could be a delayed effect of paricalcitol treatment.
authors.affiliation: Department of Dialysis, Clinic for Internal Medicine, University Clinical Centre Maribor, Maribor, Slovenia.
authors.forename: Robert
authors.initials: R
authors.lastname: Ekart
authors.affiliation: Department of Nephrology, Clinic for Internal Medicine, University Clinical Centre Maribor, Maribor, Slovenia.
authors.forename: Sebastjan
authors.initials: S
authors.lastname: Bevc
authors.affiliation: Department of Nephrology, Clinic for Internal Medicine, University Clinical Centre Maribor, Maribor, Slovenia.
authors.forename: Radovan
authors.initials: R
authors.lastname: Hojs
authors.affiliation: Department of Nephrology, Clinic for Internal Medicine, University Clinical Centre Maribor, Maribor, Slovenia.
authors.forename: Nina
authors.initials: N
authors.lastname: Hojs
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000419:Albuminuria / Q000188:drug therapy* / Q000453:epidemiology / Q000378:metabolism; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D004872:Ergocalciferols / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011507:Proteinuria / Q000188:drug therapy* / Q000453:epidemiology / Q000378:metabolism; D051436:Renal Insufficiency, Chronic / Q000188:drug therapy* / Q000453:epidemiology / Q000378:metabolism; D016896:Treatment Outcome; D028761:Withholding Treatment / Q000639:trends
chemical_list: D050071:Bone Density Conservation Agents; D004872:Ergocalciferols; C084656:paricalcitol
keywords: ambulatory blood pressure monitoring; chronic kidney disease; paricalcitol; proteinuria; serum cystatin C